Phase II study of bleomycin (NSC-125066) therapy for large bowel cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D005069:Evaluation Studies as Topic; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012877:Skin Manifestations; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin